Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

On October 6, 2026 Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") reported that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE with two additional exclusive targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "The addition of two new exclusive targets further validates the value and versatility of ENHANZE as the leading platform for rapid, large-volume subcutaneous delivery. As more companies seek to focus on patient convenience, reducing treatment burden and expanding access to important therapies, ENHANZE continues to be the technology of choice. This expanded agreement strengthens our growing portfolio of partnered programs and reinforces the significant long-term opportunity for ENHANZE across a broad range of therapeutic areas."

"Our partnership with Halozyme shows what co-creation can do for patients," said Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx. "Together, we brought VYVGART Hytrulo to people living with MG and CIDP, which gave patients a subcutaneous option that fits more easily into their lives. Expanding to two more targets lets us bring that same focus on patient experience to more of our pipeline as we build a broader immunology portfolio. We’re proud to keep building on a partnership, rooted in shared ambition and scientific rigor."

Halozyme is eligible to receive payments upon achievement of agreed upon milestones and will receive royalties on net sales of products using ENHANZE.

(Press release, Halozyme, OCT 6, 2026, View Source [SID1234673234])